TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.

Jorge E Cortes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.